Files IND for clinical testing of TCMP-80, a T-cell modulatory peptide, in the treatment of multiple sclerosis. Trials of the synthetic peptide are slated to begin this spring in San Diego. Frim has an NDA pending for a subcutaneous anti-allergy compound, pentigetide, with submissions planned for nasal and ophthalmic formulations later this year.
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.